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Abstract
Cardiovascular diseases, including ventricular arrhythmias are responsible for increased
mortality in patients with acromegaly. Acromegaly may cause repolarization abnormalities
such as QT prolongation and impairment of repolarization reserve enhancing liability to ar-
rhythmia. The aim of this study was to determine the short-term beat-to-beat QT variability
in patients with acromegaly. Thirty acromegalic patients (23 women and 7 men, mean age
±SD: 55.7±10.4 years) were compared with age- and sex-matched volunteers (mean age
51.3±7.6 years). Cardiac repolarization parameters including frequency corrected QT inter-
val, PQ and QRS intervals, duration of terminal part of T waves (Tpeak-Tend) and short-term
variability of QT interval were evaluated. All acromegalic patients and controls underwent
transthoracic echocardiographic examination. Autonomic function was assessed by means
of five standard cardiovascular reflex tests. Comparison of the two groups revealed no sig-
nificant differences in the conventional ECG parameters of repolarization (QT: 401.1±30.6
ms vs 389.3±16.5 ms, corrected QT interval: 430.1±18.6 ms vs 425.6±17.3 ms, QT disper-
sion: 38.2±13.2 ms vs 36.6±10.2 ms; acromegaly vs control, respectively). However, short-
term beat-to-beat QT variability was significantly increased in acromegalic patients (4.23
±1.03 ms vs 3.02±0.80, P<0.0001). There were significant differences between the two
groups in the echocardiographic dimensions (left ventricular end diastolic diameter: 52.6
±5.4 mm vs 48.0±3.9 mm, left ventricular end systolic diameter: 32.3±5.2 mm vs 29.1±4.4
mm, interventricular septum: 11.1±2.2 mm vs 8.8±0.7 mm, posterior wall of left ventricle:
10.8±1.4 mm vs 8.9±0.7 mm, P<0.05, respectively). Short-term beat-to-beat QT variability
was elevated in patients with acromegaly in spite of unchanged conventional parameters of
ventricular repolarization. This enhanced temporal QT variability may be an early indicator
of increased liability to arrhythmia.
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Introduction
Hypertension, left ventricular hypertrophy, asymmetric septal hypertrophy, cardiomyopathy,
and congestive heart failure are well-known cardiovascular complications of acromegaly
caused by pituitary tumors [1]. Excessive secretion of growth hormone and IGF-1 can result in
major structural and functional changes in cardiac system and arrhythmias, hypertension, and
valvular heart disease are present in up to 60% of patients by the time of the diagnosis of acro-
megaly [1]. Clinical data suggest that a specific cardiomyopathy develops in acromegaly associ-
ated with life-threatening dysrhythmias [2]. Complex morphological and functional
remodeling may be partially reversed by effective control of growth hormone and IGF-1 con-
centrations [2]. Moreover, acromegaly can also be associated with cardiovascular diseases con-
tributing to increased mortality among patients [1,2]. Effective control of acromegaly with
pegvisomant, a GH receptor antagonist, led to a significant improvement of Framingham risk
score, and reduced the likelihood for development of coronary heart diseases, too [3].
Electrocardiographic studies also indicated cardiac rhythm abnormalities in patients with
acromegaly [2,4,5]. Dysrhythmias, atrioventricular conduction delay and sick sinus syndrome
were reported in sudden death in acromegalic heart disease [6]. Rodrigues et al. [7] found ar-
rhythmias in 41% of 34 patients with acromegaly, thirteen patients had frequent ventricular ex-
trasystoles and there were long periods of asymptomatic ventricular bigeminy in one patient.
Both prevalence and severity of ventricular arrhythmia were significantly higher in acromegalic
patients compared to controls, and the frequency of ventricular premature complexes in-
creased with duration of acromegaly [8]. Higher incidence of late potential positivity, QT inter-
val prolongation and higher QT dispersion in acromegaly patients might explain the increased
susceptibility to sudden cardiac deaths from ventricular tachyarrhythmias [9]. Herrmann et al.
[10] detected late potentials, a predictor of ventricular dysrhythmias in a signal-averaged elec-
trocardiogram, in 56% of patients with active acromegaly (n = 16) and 6% of well-controlled
patients (n = 32) and speculated that late potentials might indicate myocardial remodeling in
acromegaly. In another study, the occurrence of late potentials were 22.9% in acromegalic vs
2.9% in control patients (P<0.001; n = 70 in both groups) and a significant association with
premature ventricular complexes were seen by means of 24-h Holter ECG recording [11]. Maf-
fei et al. [11] also described that one case of sudden cardiac death occurred during the observa-
tion period, and this acromegalic patient had late potentials, left ventricular hypertrophy,
Lown 4 premature ventricular complexes, and non-sustained ventricular tachycardia.
The identification of patients with risk for serious ventricular arrhythmia and sudden cardi-
ac death could be important during the diagnosis and treatment of acromegaly. Fatti et al. [12]
described that octreotide, a somatostatin analogue, could improve abnormally prolonged QT
interval in acromegalic patients. Treatment with GH receptor antagonist Pegvisomant for
6-month and 18-month (long-term) also improved rhythm abnormalities in 13 patients suffer-
ing from acromegaly [13]. However, QT interval prolongation alone cannot reliably predict the
development of ventricular arrhythmias including the chaotic ventricular tachycardia, Tor-
sades de Pointes (TdP), since cardiac repolarization reserve may be reduced even without sig-
nificant changes in the duration of cardiac repolarization [14]. The short-term variability of
the duration of repolarization (STVQT) [15] might be a better parameter to predict serious ven-
tricular arrhythmias and sudden cardiac death, as it has been suggested by both animal experi-
mental work [16–19] and recent clinical studies [20–23]. On the basis of these observations,
Varkevisser et al. [24] suggested that beat-to-beat STVQT could be superior to QT interval pro-
longation in identifying patient populations at risk for ventricular arrhythmias and might be
able to accurately predict individual risk. The aim of the present study was to determine beat-
to-beat QT variability in patients with acromegaly.
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Methods
Patient Population
Patients with acromegaly who are followed at the 1st Department of Internal Medicine in Sze-
ged, Hungary, were eligible for this study. Patients were excluded if they had excessive (>5%)
ectopic atrial or ventricular beats, were in a rhythm other than normal sinus, had repolarization
abnormalities (i.e. early repolarization pattern, T wave inversion and complete left bundle
branch block or right bundle branch block), had a permanent pacemaker or any other disor-
ders such as serious retinopathy, symptomatic cardiac and pulmonary disease, acute metabolic
disease, had excessive noise on the electrocardiographic signal that precluded analysis of the
ECG waveform, were on any medication likely to affect the investigated ECG parameters or
consumed significant amount of food within 3 hours or drank alcohol, coffee or smoked within
10 hours.
We studied 30 acromegalic patients, 7 males and 23 females with the age of 55.7 ± 10.4
years (all values presented are mean ± SD). A total of 30 age- and sex-matched volunteers
(mean age 51.3 ± 7.6 years) without a history or evidence of heart disease were enrolled in the
study as controls. All of the control individuals and acromegaly patients were of Caucasian ori-
gin. Acromegalic patient group was also divided to subgroups on the basis of medical examina-
tions and serum diagnostic tests performed (hGH rhythm, IGF-1 level, HbA1c concentration,
oral glucose tolerance test). Active acromegalic subgroup included acromegalic patients before
hypophysectomy or with remnant hormonally active tumor after hypophysectomy (n = 14), as
well as treated acromegalic patients with high serum IGF-1 levels in spite of long-acting so-
matostatin analogue octreotide or lanreotide therapy received (n = 3). Inactive acromegalic
subgroup included acromegalic patients after successful hypophysectomy (n = 6) and treated
acromegalic patients with an age-sex-appropriate normal IGF-1 and/or random GH< 1 ng
ml-1 and/or nadir GH after OGTT< 0.4 ng ml-1 during bromocriptine, pegvisomant, or long-
acting somatostatin analogue octreotide treatments (n = 7). There was no significant age differ-
ence between the active and inactive patients (56.4 ± 11.5 vs 54.8 ± 9.2 years, respectively;
P = 0.69). In acromegaly group, there were 18 hypertensive patients receiving therapy (for de-
tails see S1 Table) and 12 normotensive subjects, whereas volunteers in control group did not
receive antihypertensive treatment.
The studies described here were carried out in accordance with the Declaration of Helsinki
(2000) of the World Medical Association and were approved by the Scientific and Research
Ethical Committee of the Medical Research Council at the Hungarian Ministry of Health
(ETT-TUKEB), under ethical approval No. 4987-0/2010-1018EKU (338/PI/010). All subjects
have given written informed consent of the study.
Data Collection and Analysis
12-lead electrocardiograms were continuously recorded for 5 min at rest, in the supine position
to obtain signals with the least amount of motion artefact. In all leads the ECG signals were dig-
itized at 2000 Hz sampling rate with a multichannel data acquisition system (Cardiosys-H1
software, Experimetria Ltd, Budapest, Hungary) connected to a personal computer and stored
for later off-line analysis.
Out of the repolarization parameters we analyzed the frequency corrected QT interval
(QTc) using Bazett’s (QTc = QT/
p
RR), Fridericia (QTc = QT/[RR/1000]1/3), Framingham
(QTc = QT + [0.154  {1000-RR}]) and the Hodges formulas (QTc = QT + 1.75  [60 000/RR-
60]), the QT dispersion (QTd), the PQ and QRS intervals, the duration of terminal part of T
waves (Tpeak-Tend) and the short-term variability of QT interval (STVQT).
Short-Term Qt-Variability in Acromegaly
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The RR and QT intervals and duration of the T wave from the peak to the end (Tpeak-Tend)
intervals were measured automatically in 30 consecutive beats (minimum number of intervals
needed for variability measurements), were checked by the same expert investigator of the team
for all ECGs and manually corrected if needed and were calculated as the average of 30 beats.
QTc interval duration was defined as the mean duration of all QTc intervals measured. The PQ
and QRS intervals were measured as the average of 15 consecutive beats. All measurements were
carried out using limb lead II and in case of excessive noise in limb lead II and lead V5.
To characterize the temporal instability of beat-to-beat repolarization, Poincaré plots of the
QT intervals were constructed, where each QT value is plotted against its former value. STVQT
was calculated using the following formula: STVQT = ∑|QTn+1-QTn|/(30x
p
2), where QT repre-
sents the duration of the QT interval. This calculation defines the STV as the mean distance of
points perpendicular to the line of identity in the Poincaré plot and relies on previous mathe-
matical analysis (25).
All acromegalic patients and controls also underwent transthoracic echocardiographic ex-
amination performed by the single observer blinded to subject data for all participants. Two-di-
mensional echocardiographic images were obtained by Toshiba Powervision 8000
echocardiography equipment, in a number of cross-sectional planes using standard transducer
positions to determine standard morphological and functional parameters.
Autonomic function was assessed by means of five standard cardiovascular reflex tests: the
heart rate (HR) responses to deep breathing and to standing up (30/15 ratio), the Valsalva ma-
neuver, the systolic blood pressure response to standing up, and the diastolic pressure change
during a sustained handgrip. A score was created to express the severity of autonomic neuropa-
thy (AN), based on the results of the five tests (normal: 0, borderline: 1, abnormal: 2). The total
score was in the interval of 0 to 10.
Fasting venous blood samples were obtained from each patient and controls for the determi-
nation of serum glucose, blood urea nitrogen, creatinine, sodium and potassium levels. GH and
IGF-1 were measured by chemiluminescent immunoassay (IMMULITE 1000 Immunoassay
System, Siemens. GH measurement comparator: Recombinant 98/574; detection limit: 0.01 ng
ml-1; intra-assay coefficients of variation: 6.0%; interassay coefficients of variation: 6.2%. IGF-1
measurement comparator: WHO IRP 87/517; detection limit: 20.0 ng ml-1; intra-assay coeffi-
cients of variation: 5.0%; interassay coefficients of variation: 9.0%).
Statistical Analysis
All data are expressed as mean±SD. Comparisons between acromegalic patients and controls
for the study variables were done using the unpaired Student’s t test for normally distributed
parameters, nonparametric Mann-Whitney U test for non-normal distributions, and linear re-
gression for revealing correlations. The statistical analyses were performed using the SPSS 16.0
software package. Statistical significance was accepted at the P<0.05 level.
Results
Clinical data of acromegalic patients and control subjects
In 30 acromegalic patients studied, body weight and mean body mass index (BMI) were signifi-
cantly higher (P<0.001 for both parameters) than those in age- and sex-matched volunteers
(Table 1). Mean systolic blood pressure did not differ significantly between control subjects
and acromegalic patients receiving standard care and treatment, however, acromegalic patients
had higher diastolic blood pressure (P<0.05). The incidence of high blood pressure was 7/30 in
control and 13/30 in acromegaly groups during the actual measurements. Average serum glu-
cose and HbA1c values were also similar in both groups; incidences of diabetes were 0/30 and
Short-Term Qt-Variability in Acromegaly
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1/30 in control and acromegaly groups, respectively. Incidence of impaired glucose tolerance
was 0/30 in control and 4/30 in acromegalic subjects. Significant differences were seen in
serum hGH (P = 0.0028) and IGF-1 (P = 0.0013) levels between acromegalic and control
groups. There was no significant difference in nadir value of hGH during oral glucose tolerance
test (OGTT) between active (3.40 ± 2.10 ng/ml) and inactive (1.80 ± 1.86 ng/ml) acromegalic
subgroups. However, significantly higher average hGH (7.00 ± 6.73 ng/ml vs 2.03 ± 2.86 ng/ml,
P = 0.0180) and IGF-1 (501.3 ± 359.6 ng/ml vs 198.5 ± 79.1 ng/ml, P = 0.0060) concentrations
were measured in active acromegalic subgroup compared to inactive one.
Echocardiography measurements in study subjects
There were significant differences between the two groups in the echocardiographic dimen-
sions. Patients with acromegaly exhibited significantly higher values in left ventricular end dia-
stolic and end systolic diameter and in interventricular septum, left ventricular posterior wall
thickness compared to age-matched controls (Table 2). These results were not unexpected and
Table 2. Echocardiographic parameters in patients with acromegaly and age-matched controls.
Control Acromegaly
EF (%) 70.6 ± 5.4 67.2 ± 6.9*
EDD (mm) 48.0 ± 3.9 52.6 ± 5.4*
ESD (mm) 29.1 ± 4.4 32.3 ± 5.2*
IVS (mm) 8.8 ± 0.7 11.1 ± 2.2**
PW (mm) 8.9 ± 0.7 10.8 ± 1.4**
Abbreviations: EF: ejection fraction; EDD: left ventricular end diastolic diameter; ESD: left ventricular end




Table 1. Clinical data of acromegalic patients and age-matched control subjects.
Control Acromegaly
Age (years) 51.3 ± 7.6 55.7 ± 10.4
Weight (kg) 68.9 ± 14.7 87.7 ± 19.3**
Height (cm) 165.1 ± 10.5 168.9 ± 8.2
BMI (kg m-2) 25.1 ± 3.7 30.6 ± 5.3**
Systolic BP (mmHg) 126.9 ± 13.4 133.2 ± 17.7
Diastolic BP (mmHg) 75.5 ± 8.5 82.7 ± 12.4*
0 min glucose (mmol l-1) 5.04 ± 0.52 5.40 ± 0.71
120 min glucose (mmol l-1) 5.30 ± 1.30 6.30 ± 2.53
HbA1c (%) 5.70 ± 0.50 5.90 ± 0.74
hGH nadir following OGTT (ng ml-1) 1.02 ± 1.42 2.72 ± 2.13*
IGF-1 (ng ml-1) 151.0 ± 51.4 370.1 ± 311.8*
IGF-1 x ULN 0.50 ± 0.33 x ULN 1.66 ± 1.59 x ULN**
Abbreviations: BMI: body mass index; BP: blood pressure; HbA1c: glycosylated hemoglobin; hGH: human
growth hormone; IGF-1: insulin-like growth factor-1; OGTT: oral glucose tolerance test; ULN: upper limit of
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were supportive of the presence of myocardial hypertrophy of in the acromegalic patients and
could be related to the duration and activity of the disease. However, no significant difference
was detected in the echocardiographic parameters measured between active and inactive acro-
megaly subgroups (EF: 66.7 ± 7.4% vs 67.9 ± 6.4%, EDD: 52.6 ± 4.9 mm vs 52.7 ± 6.1 mm, ESD:
32.1 ± 5.9 mm vs 32.5 ±4.3 mm, IVS: 10.6 ± 1.3 mm vs 11.8 ± 3.0 mm, PW: 10.5 ± 1.3 mm vs
11.2 ± 1.6 mm, respectively).
Electrocardiographic parameters in study subjects
Comparison of the two groups (acromegalic patients vs control) revealed no significant differ-
ences in heart rate, the PQ, QRS and QT intervals and the QT dispersion. In order to reliably
assess the duration of ventricular repolarization and to minimize the influence of changing
heart rate on the QT interval, frequency correction of the QT interval (QTc) was performed by
the Bazett, Fridericia, Framingham and Hodges formulas. QTc values calculated with all the
four formulas showed no significant differences between acromegalic patients and controls.
However, the Tpeak-Tend interval was significantly increased in acromegalic patients compared
to controls (Table 3). Electrocardiographic parameters tended to be shorter in active acromega-
ly subgroup compared to the data measured in inactive subgroup (RR: 859.8 ± 134.5 ms vs
901.0 ± 178.2 ms, not significant (NS), QT: 392.7 ± 28.5 ms vs 412.0 ±29.5 ms, NS; QTc Bazett:
425.0 ± 16.0 ms vs 436.8 ±20.3 ms, NS; QTc Friderica: 413.7 ± 15.6 ms vs 428.1 ±16.6 ms, P =
0.0220; QTc Framingham: 414.3 ± 14.9 ms vs 427.3 ±17.8 ms, P = 0.0376; QTc Hodges:
412.5 ± 15.4 ms vs 426.9 ±16.7 ms, P = 0.0209; Tpeak—Tend: 86.0 ± 15.7 ms vs 84.7 ±11.0 ms,
NS, respectively).
Short-term beat-to-beat variability of the QT intervals
To characterize the instability of cardiac ventricular repolarization, the short-term beat-to-beat
variability of the QT interval was calculated in acromegalic patients and age-matched controls.
As individual representative examples (Poincaré plots, Fig 1) and grouped average data show
STVQT was significantly increased by 36% in acromegalic patients compared to controls
Table 3. ECG parameters in patients with acromegaly and age-matched controls.
Control Acromegaly
RR (ms) 840.0 ± 75.0 877.6 ± 153.4
PQ (ms) 158.2 ± 17.7 158.0 ± 17.3
QRS (ms) 92.2 ± 6.5 95.3 ± 8.4
QT (ms) 389.3 ± 16.5 401.1 ± 30.0
QTc (ms) Bazett 425.6 ± 17.3 430.1 ± 18.6
QTc (ms) Fridericia 413.1 ± 14.5 419.9 ± 17.4
QTc (ms) Framingham 414.0 ± 13.7 419.9 ± 17.2
QTc (ms) Hodges 410.4 ± 13.8 418.7 ± 17.3*
QTd (ms) 36.6 ± 10.2 38.2 ± 13.2
Tpeak-Tend (ms) 80.0 ± 10.3 85.5 ± 13.6
STVQT (ms) 3.02 ± 0.80 4.23 ± 0.10**
Abbreviations: QTc: frequency corrected QT interval; QTd: QT dispersion; STVQT: short-term variability of
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(4.23 ± 0.10 ms vs 3.12 ± 0.80, P<0.0001) (Fig 2). STVQT values did not differ significantly be-
tween active (4.16 ± 0.89 ms) and inactive (4.33 ± 1.22 ms) acromegalic patient subgroups.
There was no difference between acromegalic subjects treated with antihypertensive drugs
(4.33 ± 0.95 ms, n = 18) and normotensive acromegalic patients (4.10 ± 1.16 ms, n = 12). We
could not find any significant correlation between the STVQT values and the left ventricular hy-
pertrophy parameters in acromegaly patients or in the sub-groups of active and inactive pa-
tients (data not shown).
Fig 1. Representative Poincaré plots of a control individual and a patient with acromegaly. Note the
larger area covered by data points obtained in the acromegalic patient illustrating increased short-term
variability of the QT interval. Abbreviations: QTc, corrected QT interval by Bazett formula; STVQT, short-term
variability of the QT interval.
doi:10.1371/journal.pone.0125639.g001
Fig 2. Short-term beat-to-beat temporal variability of the QT interval (STVQT) in acromegalic and
matched control patients. Individual values measured in n = 30 patients in each group are presented, the
blue lines indicate mean values, P<0.001.
doi:10.1371/journal.pone.0125639.g002
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Autonomic function
Standard cardiovascular reflex tests indicated significant deteriorations in Valsalva ratio
(P = 0.0015), 30/15 ratio (P = 0.0143), and AN score (P = 0.0023) in patients with acromegaly,
however, no significant differences in systolic blood pressure response after standing up, and
diastolic blood pressure response after sustained handgrip were detected between the two
groups (Table 4). AN score was significantly lower in active acromegaly subgroup, than in inac-
tive group (2.1 ± 1.7 vs 3.9 ± 2.2; P = 0.0260), whereas other autonomic functions measured did
not differ significantly in our two acromegalic subgroups (heart rate variation during deep
breathing: 15.5 ± 6.5 min-1 vs 11.9 ± 7.95 min-1; Valsalva ratio: 1.50 ± 0.26 vs 1.40 ± 0.29; 30/15
ratio: 1.10 ± 0.13 vs 1.10 ± 0.29; Systolic blood pressure fall after standing up: 8.6 ± 11.8 mmHg
vs 9.8 ± 6.2 mmHg; Diastolic blood pressure increase after handgrip: 19.1 ± 8.2 mmHg vs
15.4 ± 8.2 mmHg; respectively). There was no significant difference between the values of auto-
nomic parameters measured in acromegalic subjects treated with antihypertensive drugs and
normotensive patients with acromegaly.
Correlation of serum hGH and IGF-1 x ULN levels with cardiovascular
data and autonomic neuropathy parameters
Pearson coefficient values indicated that neither hGH nor IGF-1 x ULN hormone level corre-
lated with STVQT or any other ECG parameters measured (Table 5). However, serum hGH
concentration negatively correlated with diastolic blood pressure (P = 0.0326), thickness of
posterior wall of left ventricle (P = 0.0333), and AN score (P = 0.0131), whereas IGF-1 x ULN
levels positively correlated with Valsalva ratio (P = 0.0087).
Discussion
Although a connection between acromegaly and increased cardiovascular morbidity and mor-
tality has been established previously, this study is the first to demonstrate increased beat-to-
beat short-term variability of the QT interval in acromegalic patients. There was no significant
difference between STVQT values measured in clinically and biochemically active acromegalic
patients and those in inactive patients, which may suggest that elevated STVQT is related to the
presence of acromegaly and not to the efficacy of the treatments applied. STVQT is a novel
ECG parameter that, according to experimental [16–18] and clinical [20–23] data, more reli-
ably predicts the development of serious ventricular arrhythmia compared to conventional
Table 4. Autonomic neuropathy parameters of acromegalic patients and age-matched control
subjects.
Control Acromegaly
Heart rate variation during deep breathing (1/min) 17.20 ± 6.44 14.00 ± 7.22
Valsalva ratio 1.70 ± 0.34 1.40 ± 0.28*
30/15 ratio 1.20 ± 0.18 1.10 ± 0.21*
Systolic BP fall after standing up (mm Hg) 6.40 ± 6.77 9.10 ± 9.66
Diastolic BP increase after sustained handgrip (mm Hg) 20.00 ± 9.22 17.50 ± 8.2
AN score 1.50 ± 1.28 2.90 ± 2.11*
Abbreviations: AN, autonomic neuropathy; BP, blood-pressure; 30/15 ratio, immediate heart rate response
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ECG parameters of repolarization. STVQT values may be used to help predict individual risk
for arrhythmia and sudden cardiac death in patients with acromegaly, however, the efficacy of
this approach could only be confirmed during prospective clinical studies.
Cardiac rhythm abnormalities have been demonstrated by electrocardiogram and Holter
studies in acromegaly [4,5]. Resting electrocardiological changes included left axis deviation,
increased QT intervals, septal Q-waves, ST-T wave depression, and late potentials in acrome-
galic patients [7,10]. Atrial and ventricular ectopic beats, paroxysmal atrial fibrillation, parox-
ysmal supraventricular tachycardia, sick sinus syndrome, bundle branch block, and ventricular
tachycardia were seen during physical exercise [4,5]. The severity of ventricular arrhythmias
correlated with increases in left ventricular mass and the frequency of ventricular premature
complexes increased with the duration of acromegaly [8]. Fatti et al. [12] detected abnormally
long QTc interval before treatment in one-quarter of 30 acromegalic patients in a retrospective
study. Octreotide, a somatostatin analogue, was shown to reduce QT intervals [12], and reduce
the number of ventricular premature complexes in acromegalic patients [26].
Table 5. Correlation of serum average hGH and IGF-1 x ULN level of acromegalic patients with cardiovascular data and autonomic neuropathy
parameters.
Serum average hGH level (ng ml-1) Serum IGF-1 x ULN level
Pearson r P value (two-tailed) Pearson r P value (two-tailed)
Systolic BP (mmHg) - 0.2294 0.2313 0.3206 0.0900
Diastolic BP (mmHg) - 0.3978 0.0326* 0.1256 0.5161
EF (%) 0.3170 0.0878 -0.1735 0.3593
EDD (mm) - 0.2911 0.1186 -0.1680 0.3749
ESD (mm) - 0.3507 0.0574 -0.1076 0.5716
IVS (mm) - 0.2714 0.1469 0.0388 0.8387
PW (mm) - 0.3897 0.0333* 0.1048 0.5815
RR (ms) - 0.1204 0.5262 - 0.1045 0.5826
PQ (ms) - 0.1968 0.2974 - 0.0284 0.8817
QRS (ms) - 0.0127 0.9468 - 0.3023 0.1044
QT (ms) - 0.2032 0.2815 - 0.2360 0.2092
QTc (ms) Bazett - 0.1090 0.5663 - 0.2084 0.2690
QTc (ms) Fridericia - 0.1992 0.2914 - 0.2919 0.1175
QTc (ms) Framingham - 0.1834 0.3320 - 0.2690 0.1506
QTc (ms) Hodges - 0.2154 0.2530 - 0.2975 0.1103
QTd (ms) 0.1562 0.4099 0.1758 0.3526
Tpeak-Tend (ms) - 0.0917 0.6298 - 0.0788 0.6791
STVQT (ms) - 0.3401 0.0659 - 0.0924 0.6272
Heart rate variation during deep breathing (1/min) 0.2300 0.2390 - 0.1267 0.5206
Valsalva ratio 0.1340 0.4967 0.4864 0.0087*
30/15 ratio 0.2386 0.2307 0.0167 0.9342
Systolic BP fall after standing up (mm Hg) - 0.3617 0.0586 - 0.2206 0.2593
Diastolic BP increase after sustained handgrip (mm Hg) 0.2421 0.2146 - 0.0762 0.6998
AN score - 0.4714 0.0131* - 0.2077 0.2987
Abbreviations: 30/15 ratio, immediate heart rate response to standing; AN, autonomic neuropathy; BP: blood pressure; EDD: left ventricular end diastolic
diameter; EF: ejection fraction; ESD: left ventricular end systolic diameter; hGH: human growth hormone; IGF-1: insulin-like growth factor-1; ULN: upper
limit of normal value; IVS: interventricular septum; PW: posterior wall of left ventricle; QTc: frequency corrected QT interval; QTd: QT dispersion; STVQT:
short-term variability of QT interval; n = 30 for each number of XY pairs,
*P<0.05 for correlation.
doi:10.1371/journal.pone.0125639.t005
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Acromegalic cardiomyopathy is frequently present at diagnosis and the majority of patients
with acromegaly meet echocardiographic criteria for left ventricular hypertrophy [5]. A possible
reason is that acromegalic patients are sometimes diagnosed only after longer duration (7–10
years) of the disease. No significant difference in left ventricle hypertrophy was observed be-
tween active and inactive acromegaly patients in our study, which may indicate that adequate
treatment of acromegaly could not turn back the process. Cardiac performance of acromegalic
patients during physical exercise depends on left ventricular diastolic function under resting
condition [27]. Ciulla et al. [28] found elevated myocardial echoreflectivity and increased QTd
in acromegalic patients and explained these changes by long-term, blood pressure-independent
cardiac hypertrophy and prolonged exposure to high serum concentrations of hGH and IGF-1.
Baykan et al. [29] analyzed echocardiographic parameters by tissue and two-dimensional Dopp-
ler imaging in acromegalic patients and found that GH level positively correlated with interven-
tricular septum thickness. Our observations regarding these parameters were unexpectedly
different. Myocardial hypertrophy in relevant animal models has been shown to result in
electrophysiological remodeling where the expression of potassium channels critical for repolar-
ization and repolarization reserve (such as IKs), is significantly reduced, creating an arrhythmia
substrate of increased spatial heterogeneity and temporal instability of repolarization and lead-
ing to increased arrhythmia susceptibility in the heart [14,30–32]. Patients with acromegaly may
also develop congestive heart failure, the ratio was less than 3% (10 of 330 consecutive patients)
in a study performed in 2 centers [33]. Recent studies indicated that IKs, IKr, IK1, and Ito potassi-
um channels were down-regulated [34–36] and the persistent or slowly-inactivating sodium cur-
rent was also increased in chronic heart failure [37]. Additionally, acromegalic patients could
also develop coronary heart disease and most patients have systemic complications affecting the
Framingham risk score [38]. GH receptor antagonist therapy improved the score and reduced
the risk for coronary heart diseases [3]. In acromegalic patients, increased stiffness of ascending
aorta was described [39] and ambulatory arterial stiffness indexes might have an important role
in predicting cardiovascular risk [40]. Several mechanisms have been implicated in the develop-
ment of ventricular arrhythmias in the settings of myocardial ischemia and myocardial infarc-
tion [41]. The surviving ventricular myocytes in the border zone next to the infarcted area play a
particularly important role in the development of arrhythmias [42,43]. In these cells, a consistent
downregulation of different potassium channels has been found, including Ito [42], IK1 [44], IKr
and IKs [45]. The QT variability index, among the first ECG parameters used to characterize
temporal variability of repolarization, has been shown to more reliably predict myocardial ische-
mia and myocardial infarction associated serious ventricular arrhythmia development com-
pared to more conventional ECG parameters [15,46,47]. It should be noted that myocardial
fibrosis occurring in acromegaly [48] can also contribute to the underlying arrhythmia substrate
in the heart due to disturbances in conduction.
Animal studies support the cardiovascular findings of clinical observations on acromegalic
patients. Overexpression of bovine GH gene increased cardiac mass, induced hypertrophy of
left ventricle, and deteriorated cardiac systolic function in adult female transgenic mice [49].
The long-term exposure to high serum GH concentration also resulted in impaired high-ener-
gy phosphate metabolism and mitochondrial ultrastructural changes in the heart muscle of
mice [49]. Bovine GH transgenic mice also developed a salt-resistant form of hypertension and
structural narrowing of the resistance vasculature [50].
Our observations indicate deterioration in autonomic function assessed by standard cardio-
vascular reflex tests in acromegalic patients. AN score was significantly worse in inactive acro-
megalic patients and there was no apparent difference between acromegalic subgroups in other
autonomic parameters measured, which may suggest that these neuropathy parameters are
long-term consequences of acromegaly and cannot be reverted by the control of the disease.
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Among the tests primarily reflecting parasympathetic functions, the Valsalva ratio and 30/15
ratio were significantly decreased in acromegaly, whereas heart rate variation during deep
breathing was not changed significantly. The tests demonstrating sympathetic activity, such as
systolic blood pressure fall after standing up and diastolic blood pressure increase after sus-
tained handgrip, did not change significantly in acromegalic patients. These reflex tests indicate
a moderate parasympathetic dysfunction in our study, which could represent a predisposition
to proarrhythmic activity in acromegalic patients. Increased risk of sudden cardiac death and
ventricular arrhythmia has been associated with decreased parasympathetic and increased
sympathetic activity [51]. Parasympathetic activation has been considered as antiarrhythmic
regarding the development of ventricular fibrillation in pathological settings; for a recent re-
view see [52]. There are conflicting data published about the cardiac autonomic functions in
patients with acromegaly [53–57]. Dural et al. [53] provided evidence of sympathovagal imbal-
ance due to sympathetic hypertone in acromegalic patients. Acromegaly was significantly asso-
ciated with cardiac autonomic dysfunction independent from the presence of hypertension or
diabetes mellitus [53]. Comunello et al. [54] analyzed 24 h frequency domain heart rate vari-
ability and found a correlation between reduced sympathovagal balance and pathological con-
ditions, such as diabetes or hypertension in acromegalic patients. Chemla et al. [55] found that
10±6 months successful treatment of acromegaly could increase parasympathetic modulation
and decrease sympathetic modulation of the night time heart variability and this effect was un-
related to changes in sleep apnea status. In contrast to our observations, sympathovagal imbal-
ance due to increased vagal tone was demonstrated as a new risk factor for arrhythmias and
syncope in acromegalic patients with left ventricle hypertrophy, although with normal heart
rate, normal QT interval, and normal ejection function [56]. High frequency bands in orthos-
tatism, but not in clinostatism, were higher in acromegalic patients than in normal subjects
[56]. However, Seravalle et al. [57] have recently detected significantly decreased adrenergic
tone through direct recording of muscle sympathetic nerve activity in newly diagnosed acro-
megalic patients with insulin resistance, but without cardiac hypertrophy.
Determination of beat-to-beat STVQT is an intensively investigated new and non-invasive
method for assessment of proarrhythmic risk [14,24]. QT interval measurements provide physi-
ological information regarding the duration of cardiac repolarization. However, simple QT in-
terval measurements are not always reliable in arrhythmic risk prediction. Ventricular
repolarization is governed by a fine balance of inward and outward ionic currents. Under nor-
mal conditions impairment of one type of outward potassium channels is not likely to cause ex-
cessive QT prolongation, since other types of potassium channels provide sufficient repolarizing
capacity. This was termed as repolarisation reserve [58,59]. Temporal STVQT proved to be a
more sensitive predictor of Torsades de Pointes ventricular tachycardia development than con-
ventional QT parameters, such as QT and rate corrected QT intervals or the spatial QT interval
dispersion, in case of experimentally impaired repolarization reserve [17,18,60]. There are nu-
merous examples for the association between different pathophysiological conditions and atten-
uated repolarization reserve caused by electrophysiological remodelling. In addition, in
experimental studies ventricular hypertrophy and chronic heart failure (CHF) were associated
with decreased repolarisation reserve and/or high incidence of proarrhythmic events [17,61–
63]. The significance and sensitivity of STVQT as a predictor for electrical remodelling and
proarrhythmia has recently been confirmed in clinical conditions in connection with CHF [22].
Increased STVQT in the context of moderate CHFmay reflect a latent repolarization disorder
and increased susceptibility to sudden death in patients with dilated cardiomyopathy, which is
not identified by a prolonged QT interval. In this study, increased STVQT was the strongest indi-
cator with an odds ratio of 1.52 (95% confidence interval 1.20 to 2.07, P = 0.007) for a history of
documented ventricular tachycardia [22].
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Varkevisser et al. [24] has recently reviewed the studies in which beat-to-beat STVQT was a
better indicator than QT interval prolongation for identification of healthy subjects or patients
at risk for ventricular arrhythmias. In this regard, we have recently demonstrated that profes-
sional soccer players with hypertrophied hearts had increased STVQT both in resting condi-
tions and after exercise [64]. Significantly increased baseline STVQT was able to identify
patients with diminished repolarization reserve exhibiting drug-induced Torsades de Pointes
[20] and those with inherited long QT syndrome [21]. Increase in STVQT and prolongation of
QT interval were observed in patients receiving cardiotoxic doxorubicin therapy [65]. A pro-
spective clinical trial, the EUTrigTreat clinical study, was completed to investigate arrhythmo-
genic risk factors, including beat-to-beat variability of repolarization in sudden cardiac death
risk stratification in patients with implantable cardioverter defibrillator [66]. Similar, prospec-
tive trials may elucidate the benefit of the use of STVQT in other patient populations
including acromegaly.
Increased temporal instability of cardiac repolarization characterized by elevated STVQT in
pathological situations, including acromegaly, can refer to impairment of repolarization reserve
and increased propensity for arrhythmias [14]. In this setting, even relatively weak inhibition
of potassium channels by seemingly harmless medications and/or dietary constituents may
lead to sudden and unexpected excessive QT prolongation and development of Torsades de
Pointes ventricular tachycardia [14].
Limitations of the study: It is important to note that in the present study the duration of ac-
romegaly from the diagnosis can be defined (10–30 years), however the exact onset of the dis-
ease is not determinable and furthermore the duration since the remission in the inactive
acromegalics is also not known. Therefore the real exposure time of increased hGH level before
the diagnosis and effective treatment of the disease is not known and our active and inactive
patients groups can be heterogenous in this regard. Moreover, the actual hormone levels used
for correlation calculations with echocardiography and other cardiovascular parameters do not
necessarily correspond to the duration of the disease. Because of our unexpected negative cor-
relation between the GH level and the posterior wall thickness, further echocardiographical
studies are warranted to examine the relationship between GH and IGF-1 levels and echocar-
diographic parameters in a larger series of acromegalic patients. A prospective study on newly
diagnosed acromegaly patients could answer the question whether effective treatment would
have any time-related effects on the changes in STVQT variability and autonomic cardiovascu-
lar unctions.
In conclusion, STVQT is increased in patients with acromegaly while more conventional pa-
rameters of ventricular repolarization were unchanged. STVQT values did not differ between
active and inactive acromegalic patients and did not correlate with actual serum concentrations
of hGH and IGF-1. These observations may suggest that elevated short-term beat-to-beat vari-
ability is a consequence of the disease and not related directly to current treatment or condition
of the patient. The elevated STVQT suggests instability of ventricular repolarization and may be
an early indicator of increased liability to arrhythmia in patients with acromegaly. Further pro-
spective clinical studies are needed to identify individual risk for ventricular arrhythmias in
acromegalic patients.
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